anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a single-center study with 3 cohorts (groups). Approximately 58 participants will be enrolled in this study. In Cohort 1, approximately 16 participants will be enrolled for up to 78 days and they will receive 4 different single-dose regimens (Treatment A, B, C and D) of intranasal spray of esketamine solution in a crossover manner (participants will be switched from one single-dose regimen to another) and in an open label manner (both the investigator and the participant know the intervention received by the participant). In Cohort 2, approximately 14 participants will be enrolled for up to 35 days and they will receive 1 regimen of intranasal esketamine (Treatment D) in an open label manner. In Cohort 3, approximately 28 participants will be enrolled and they will be randomly assigned to receive either Treatment E (intranasal esketamine spray) or Treatment F (intranasal placebo spray) in a double blind manner (both the investigator and the participant do not know the intervention received by the participant). Safety evaluations will include assessment of adverse events, targeted nasal examinations, laboratory tests, electrocardiogram, physical examination, pulse oximetery, and vital signs.
The management of myocardial ischemia/reperfusion (I/R) damage in the context of reperfusion treatment remains a significant hurdle in the field of cardiovascular disorders. The injured lesions exhibit distinctive features, including abnormal accumulation of necrotic cells and subsequent inflammatory response, which further exacerbates the impairment of cardiac function. Here, we report genetically engineered hybrid nanovesicles (hNVs), which contain cell-derived nanovesicles overexpressing high-affinity SIRPα variants (SαV-NVs), exosomes (EXOs) derived from human mesenchymal stem cells (MSCs), and platelet-derived nanovesicles (PLT-NVs), to facilitate the necrotic cell clearance and inhibit the inflammatory responses. Mechanistically, the presence of SαV-NVs suppresses the CD47-SIRPα interaction, leading to the promotion of the macrophage phagocytosis of dead cells, while the component of EXOs aids in alleviating inflammatory responses. Moreover, the PLT-NVs endow hNVs with the capacity to evade immune surveillance and selectively target the infarcted area. In I/R mouse models, coadministration of SαV-NVs and EXOs showed a notable synergistic effect, leading to a significant enhancement in the left ventricular ejection fraction (LVEF) on day 21. These findings highlight that the hNVs possess the ability to alleviate myocardial inflammation, minimize infarct size, and improve cardiac function in I/R models, offering a simple, safe, and robust strategy in boosting cardiac repair after I/R.
This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
OBJECTIVE: The pathological mechanism of osteoporosis (OP) involves increased bone resorption mediated by osteoclasts and decreased bone formation mediated by osteoblasts, leading to an imbalance in bone homeostasis. Identifying key molecules in osteoclast-mediated OP progression is crucial for the prevention and treatment of OP.
METHODS: Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed on the OP patient datasets from the GEO database. The results were intersected with the differential expression results from the osteoclast differentiation dataset to identify key genes. These key genes were then subjected to disease relevance analysis, and consensus clustering was performed on OP patient samples based on their expression profiles. The subgroups were analyzed for differences, followed by GO, KEGG, GSEA, and GSVA analyses, and immune infiltration. Finally, osteoclast differentiation model was constructed. After validating the success of the model using TRAP and F-actin staining, the differential expression of key genes was validated in vitro via Western blot.
RESULTS: CTRL, ARHGEF5, PPAP2C, VSIG2, and PBLD were identified as key genes. These genes exhibited strong disease relevance (AUC > 0.9). Functional enrichment results also indicated their close association with OP and osteoclast differentiation. In vitro differential expression validation showed that during osteoclast differentiation, CTRL was downregulated, while ARHGEF5, PPAP2C, VSIG2, and PBLD were upregulated, with all differences being statistically significant (P < 0.05).
DISCUSSION: Currently, there are no studies on the effects of these five genes on osteoclast differentiation. Therefore, it is meaningful to design in vivo and in vitro perturbation experiments to observe the impact of each gene on osteoclast differentiation and OP progression.
CONCLUSION: CTRL, ARHGEF5, PPAP2C, VSIG2, and PBLD show high potential as molecular targets for basic and clinical research in osteoclast-mediated OP.
The invention belongs to the technical field of medicine, and relates to 1-substituted aryl-3-(3,4,5-trimethoxyphenyl)-1,2-propanedione and derivatives of the 1-substituted aryl-3-(3,4,5-trimethoxyphenyl)-1,2-propanedione compound. The derivatives have a structure as the following, wherein X and Y are O, NOH, NOR, and NR; and R is C1-C6 alkyl. The invention also provides pharmaceutically acceptable nontoxic salts formed by the derivatives represented by the structural formula, and hydrates thereof. The pharmaceutically acceptable nontoxic salts include salts formed by the derivatives and acids. As a result of pharmacological activity tests, the derivatives have good tumor-inhibiting activities. The derivatives can be used in tumor cell antiblastics in the preparations of tumor inhibiting medicines.
FIELD: veterinary medicine. SUBSTANCE: method involves placing leeches in special kind of 12 cm long laboratory tubes of 5 cm diameter. Three leeches are placed on udder lobe skin injured with latent mastitis. After becoming satiated with blood (20-30 min), the leeches spontaneously leave the udder skin. The procedure is repeated three times with 24 h pause. After being left by leeches, the places of leech bite is disinfected and covered with bactericide plaster. EFFECT: enhanced effectiveness of treatment.
<P>PROBLEM TO BE SOLVED: To provide an oily skin lotion having high dispersibility of powder in an oil and giving excellent roughened skin ameliorating/preventing effect.  <P>SOLUTION: This oily skin lotion contains a composite powder produced by coating the surface of an oleophilic base powder with zinc oxide and an oil containing the composite powder in dispersed state. The ζ-potential of the oleophilic base powder is negative at the pH on the skin. The coating ratio of the oleophilic base powder with the zinc oxide is preferably 1-90% based on the total surface area of the powder at the dispersion of the powder in the oil. The oleophilic base powder is preferably swollen when dispersing the powder in the oil. The cosmetic can be used as a roughened skin ameliorating agent and a sensitive skin treating agent.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The rise in food intolerances and celiac disease, along with advanced diagnostic techniques, has prompted health professionals to seek effective and economical testing methods. This study evaluates combining genetic tests with routine carbohydrate-absorption breath tests to classify patients with chronic gastrointestinal disorders into therapeutic groups, enhancing dietary management and improving gut health and quality of life. Forty-nine patients with suspected carbohydrate intolerance underwent genetic testing for lactase non-persistence, hereditary fructose intolerance, and celiac disease risk. Simultaneously, breath tests assessed lactose and fructose absorption. The lactase non-persistence genotype appeared in 36.7% of cases, with one hereditary fructose-intolerance case in a heterozygous condition. Celiac disease risk markers (HLA-DQ2/8 haplotypes) were found in 49.0% of the population. Secondary lactose and/or fructose malabsorption was present in 67.3% of patients, with 66.1% of lactase non-persistence individuals showing secondary lactose malabsorption. Fructose malabsorption was prevalent in 45.8% of patients at risk for celiac disease. Two main treatment groups were defined based on genetic results, indicating primary and irreversible gastrointestinal disorder causes, followed by a sub-classification using breath test results. Genetic testing is a valuable tool for designing dietary management plans, avoiding unnecessary diet restrictions, and reducing recovery times.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Treating this condition can be challenging due to progressive fibrosis, phenotypic variations and small patient cohorts limiting the feasibility of conducting meaningful clinical trials. Although widely used, the evidence base for anti-arrhythmic drugs is limited. Beta-blockers are theoretically sound, yet their efficacy in reducing arrhythmic risk is not robust. Additionally, the impact of sotalol and amiodarone is inconsistent with studies reporting contradictory results. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.Radiofrequency ablation has shown some potential in disrupting ventricular tachycardia circuits, with combined endo and epicardial ablation yielding better results which could be considered at the index procedure. In addition, stereotactic radiotherapy may be a future option that can decrease arrhythmias beyond simple scar formation by altering levels of Nav1.5 channels, Connexin 43 and Wnt signalling, potentially modifying myocardial fibrosis.Future therapies, such as adenoviruses and GSk3b modulation, are still in early-stage research. While implantable cardioverter-defibrillator implantation is a key intervention for reducing arrhythmic death, the risks of inappropriate shocks and device complications must be carefully considered.
BACKGROUND: The Goldilocks breast reconstruction utilizes redundant mastectomy skin flaps to fashion a breast mound; however, there is concern that imbrication of these skin flaps may predispose to fat necrosis and make detection of local breast cancer recurrence more difficult. Goldilocks patients follow a traditional postmastectomy screening pathway that includes clinical examination for locoregional recurrence, but it is unclear if this is sufficient. We evaluate our Goldilocks reconstruction case series to determine rates of diagnostic imaging, biopsy, and locoregional and distant recurrence.
METHODS: Sixty-six patients (94 breasts) undergoing Goldilocks breast reconstruction were retrospectively reviewed. Any diagnostic postoperative imaging/biopsies performed and that confirmed local or distant breast cancer recurrence were noted.
RESULTS: Average time of follow-up was 45 months. Most patients in this cohort had stage 0 (27.3%) or stage I (40.9%) breast cancer. There were a total of 11 (11.7%) concerning breast masses identified. Seven (7.4%) masses were biopsied, of which 5 were benign and 2 were invasive cancer recurrence. Four masses (4.3%) underwent diagnostic imaging only, all with benign findings. Five patients in this series were found to have either distant disease or a second primary cancer in the nonoperative contralateral breast.
CONCLUSIONS: Rates of local recurrence following Goldilocks are not higher than expected after other types of postmastectomy reconstruction. Clinical monitoring successfully detected local recurrence in all affected patients in this series. More definite guidelines around the routine screening of Goldilocks mastectomy patients may aid in early detection of local breast cancer recurrence.
The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
OBJECTIVES: Use of proton pump inhibitors (PPIs) is a mainstay in treating upper gastrointestinal bleeding (UGIB). However, the beneficial effects of PPIs are not anticipated to extend beyond the duodenum and may actually contribute to the risk of lower gastrointestinal bleeding (LGIB). However, in practice, PPIs are often used for inpatients with LGIB where no benefit exists.
METHODS: A retrospective chart review was performed on inpatients during a 2-year period at an urban academic teaching hospital. Inpatients with consults to the gastroenterology (GI) service with confirmed or highly suspected LGIB were included. Outcomes regarding PPI use and the GI consulting service recommendations in these 225 patients were evaluated.
RESULTS: About 37.8% of patients were started on a PPI during their inpatient course. Of those, 46% patients started on a PPI had no indication for PPI and 85% had no recommendation by the GI consultants to start a PPI. Of the 85 patients started on PPI, the GI consultants recommended stopping it in two (2.3%) patients. Lastly, 20 patients (9%) were discharged on PPI without an indication for PPI.
CONCLUSION: To our knowledge, this is the first study that looked at the inappropriate utilization of PPIs in patients admitted for LGIBs utilizing GI consultant recommendations. Given the large proportion of patients started on PPI without a clinical indication and continued at discharge and the paucity of GI recommendations to discontinue inappropriate use, we found that clinical care may be improved with formal GI recommendations regarding use of PPI.
Each participant will first receive one-hour, one-on-one parent-child interaction strategy coaching every week via Telehealth until the parent's parent-child interaction skills and the child's social communication abilities reach a stable or upward trend, and the parent's sensory processing strategy utilization ability and the child's daily life participation scores that are continuously collected shows a stable or downward trend. After which, the one-hour, one-on-one sensory processing strategy coaching (C1) will be provided every week via Telehealth until the parent's sensory processing strategy utilization ability and the child's activity participation level reaches a stable trend.
PROBLEM TO BE SOLVED: To obtain a compound having nitrogen monoxide (NO) synthesis inhibitory effect, esp. having potent inhibitory activity against induced NO synthesis enzyme, thus useful for preventing and treating septic shock, diabetic complications, etc. SOLUTION: The objective NO synthesis enzyme inhibitor contains, as active ingredient, a 2-aminopyridine compound of the formula [R<1> and R<2> are each H, a (hydroxyl-substituted) lower alkyl or amino] or medicinally permissible salt thereof. The compound is pref. 2-amino-3-methylpyridine, 2-amino-4- methylpyridine, 2-amino-3-pyridinemethanol, etc., and can be obtained by any known method. The compound can be administered as itself, or in the form of any preparation composition permissible as a medicine, its dose being 1-300 (pref. 1-100)mg at a time pref. orally or parenterally.
A device for temporarily preventing flow of urine out of the urethra in a person suffering from urine incontinence comprises a first composition ( 11 ) enclosed in a first container ( 10 ) capable of being fed into the urethra ( 17 ) which is thereby blocked. The first container ( 10 ) comprises a mouthpiece ( 12 ) for insertion into the urethra ( 17 ) and for transport of the first composition ( 11 ) from the container ( 10 ) into the urethra ( 17 ). The first composition ( 11 ) comprises or is capable of forming a gel for blocking of the urethra by a gelatinous plug. The plug may be mechanically removed if the person wishes to urinate; alternatively the device may comprise a second composition in a second container for removal of the gel plug. In the latter alternative injection of the second composition in the urethra ( 17 ) adjacent to the gel plug causes the breakdown of the plug. Also disclosed is a corresponding method and the use of the first and second compositions in urine incontinence.
An injectable antidote for local anesthetic is disclosed. In the preferred and illustrated embodiment, it is a liquid injectable having a relatively low pH typically in the range of about 2.0 to as high as about 5.5, the preferred being about 3.5. It incorporates a biologically acceptable buffering system as for example lactic acid and a suitable salt thereof such as potassium or sodium. The system also preferably includes calcium, one form being calcium lactate. A target pH is about 3.5 for this system. In addition, a vasodilator is preferably included, and alternate additional constituents are a metabolizing agent for ester based anesthetics, and also for amide based anesthetics.
Amylase inhibitor with a polypeptide character is prepd. by extracting wheat flour, coarse ground wheat or wheat gluten with a 10-90% wt. C1-3 alcohol-water mixture, or with an aqs. electrolyte soln. at pH 1-7, and isolating the amylase inhibitor from the extract. The inhibitor has a high activity against pancreas and saliva amylase, but does not inhibit trypsin, chymotrypsin, pepsin or ribonuclease. The amylase inhibitor significantly inhibits alimentary hyperglycaemina, and is used therapeutically for the treatment of adipose conditions, arteriosclerosis and diabetes. The inhibitor can be added to starchy foods.
A mesembrine (3a-(3,4-dimethoxyphenyl)-octahydro-1-methyl-6H-indol-6-one) salt selected from mesembrine besylate, mesembrine phosphate, mesembrine tartrate, mesembrine fumarate and mesembrine succinate is provided. The preferred salt is mesembrine besylate (mesembrine benzenesulfonate) in a solid or crystalline form. A process for the preparation of a mesembrine salt comprising the steps of (a) dissolving mesembrine in a solvent; (b) adding the appropriate counterion to the solution under temperature cycling conditions; and (c) isolating the solid comprising the mesembrine salt is provided. The counterion in step (b) may be benzenesulfonic acid to give the besylate salt of mesembrine. A pharmaceutical preparation comprising a mesembrine salt selected from mesembrine besylate, mesembrine phosphate, mesembrine tartrate, mesembrine fumarate and mesembrine succinate is provided. The mesembrine salt may be used in the treatment of sexual dysfunctions such as delaying ejaculation, delaying orgasm and/or preventing premature ejaculation in a human male subject. Mesembrine besylate is highly soluble and stable with improved properties over the free-base and other salts forms, which makes it suitable for use in the manufacture of pharmaceutically acceptable drug compositions. Amorphous mesembrine besylate exists as two polymorphs.
PROBLEM TO BE SOLVED: To obtain the subject medicine enabling prevention and treatment of various kinds of diseases derived from interleukin 6 (IL-6) by including a tetronic acid derivative. SOLUTION: This medicine contains a tetronic acid derivative represented by the formula (R<1> is an alkyl, an alkenyl, an alkynyl or an aryl; R<2> is H or an acyl; R<3> is H or an alkyl; X is methylene, O, S, an alkyl or N accompanying H) or its salt as an active ingredient. The medicine can be prepared in oral or parenteral administration form and the daily doze is 1-1,000 mg and the medicine is preferably administered in one to several portions.  The medicine is useful as a therapeutic medicine for autoimmune diseases, e.g. chronic rheumatoid arthritis or systemic lupus erythematosus, a therapeutic medicine for bacterial infection, a medicine for treating septicemia shock accompanied by bacterium infection, a therapeutic medicine for virus infection, a medicine for treating cancers, e.g. multiple myeloma, a metastasis suppressant, a cancer dyscrasia- improving agent, a medicine for treating inflammatory diseases, e.g. mesangium proliferating nephritis or a medicine for treating and preventing bad conditions after extirpation operation of organs as well as osteoporosis, etc.
Once an infant is orally feeding a minimum of two times per nursing shift for four consecutive nursing shifts, the infant will be randomly assigned to receive the intervention (swaddling) or control condition (no swaddling) first, by the research OT randomly choosing an envelope with the assignment enclosed. The intervention and control feedings for each infant will be consecutive and will take place at the infant's bedside in the NICU. Infants will be assessed at each nursing care time for feeding readiness by the research OT and feeding OT according the policies of the NYU Langone Medical Center NICU, which utilizes the Infant-Driven Feeding Scale-Readiness (Appendix B) (Ludwig \& Waitzman, 2006). When the infant demonstrates readiness, the first condition will be initiated. At the next feeding when the infant demonstrates readiness, the opposite condition will be applied. If the infant is not available due to procedures or not demonstrating feeding readiness, at the next two caregiving times after the first feeding, the infant will be discontinued for that day and will start the study over the next day.
Cardiac resident MerTK+ macrophages exert multiple protective roles after ischemic injury; however, the mechanisms regulating their fate are not fully understood. In the present study, we show that the GAS6-inducible transcription factor, activating transcription factor 3 (ATF3), prevents apoptosis of MerTK+ macrophages after ischemia-reperfusion (IR) injury by repressing the transcription of multiple genes involved in type I interferon expression (Ifih1 and Ifnb1) and apoptosis (Apaf1). Mice lacking ATF3 in cardiac macrophages or myeloid cells showed excessive loss of MerTK+ cardiac macrophages, poor angiogenesis and worse heart dysfunction after IR, which were rescued by the transfer of MerTK+ cardiac macrophages. GAS6 administration improved cardiac repair in an ATF3-dependent manner. Finally, we showed a negative association of GAS6 and ATF3 expression with the risk of major adverse cardiac events in patients with ischemic heart disease. These results indicate that the GAS6-ATF3 axis has a protective role against IR injury by regulating MerTK+ cardiac macrophage survival and/or proliferation.
Patients admitted to the intensive care unit (ICU) often experience endotoxemia, nosocomial infections and sepsis. Polymorphonuclear and monocytic myeloid-derived suppressor cells (PMN-MDSCs and M-MDSCs) can have an important impact on the development of infectious diseases, but little is known about their potential predictive value in critically ill patients. Here, we used unsupervised flow cytometry analyses to quantify MDSC-like cells in healthy subjects challenged with endotoxin and in critically ill patients admitted to intensive care units and at risk of developing infections. Cells phenotypically similar to PMN-MDSCs and M-MDSCs increased after endotoxin challenge. Similar cells were elevated in patients at ICU admission and normalized at ICU discharge. A subpopulation of M-MDSC-like cells expressing intermediate levels of CD15 (CD15int M-MDSCs) was associated with overall mortality (p = 0.02). Interestingly, the high abundance of PMN-MDSCs and CD15int M-MDSCs was a good predictor of mortality (p = 0.0046 and 0.014), with area under the ROC curve for mortality of 0.70 (95% CI = 0.4-1.0) and 0.86 (0.62-1.0), respectively. Overall, our observations support the idea that MDSCs represent biomarkers for sepsis and that flow cytometry monitoring of MDSCs may be used to risk-stratify ICU patients for targeted therapy.